Compare
Pulmatrix, Inc. vs Cadrenal Therapeutics, Inc. vs Azitra, Inc. vs Petros Pharmaceuticals, Inc.
| Latest fiscal year | Pulmatrix, Inc. PULM | Cadrenal Therapeutics, Inc. CVKD | Azitra, Inc. AZTR | Petros Pharmaceuticals, Inc. PTPI |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | $0 | n/a |
| Revenue growth (YoY) | n/a | n/a | -100.0% | n/a |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/a | n/a | n/a |
| Net margin | n/a | n/a | n/a | n/a |
| Net income | -$5.16M | -$13.24M | -$10.96M | $1.91M |
| EPS (Diluted) | -$1.41 | -$6.64 | -$2.25 | -$1.56 |
| Operating cash flow | -$5.43M | -$12.60M | -$11.22M | -$6.73M |
| Free cash flow | n/a | -$12.61M | -$11.25M | n/a |
| Cash & equivalents | $4.09M | $4.01M | $2.07M | $5.14M |
| Total assets | $4.14M | $4.33M | $5.03M | $5.16M |
| Total liabilities | $329.0K | $1.59M | $1.22M | $2.29M |
| Shareholders' equity | $3.81M | $2.74M | $3.80M | $2.87M |
| Return on year-end equity | -135.5% | -483.3% | -288.2% | 66.7% |
| Shares outstanding | 3.65M | 2.34M | 10.74M | 42.28M |
Revenue, most recent five fiscal years
| Fiscal year | Pulmatrix, Inc. | Cadrenal Therapeutics, Inc. | Azitra, Inc. | Petros Pharmaceuticals, Inc. |
|---|---|---|---|---|
| Latest | $7.81M Ended 2024-12-31 | n/a | $0 Ended 2025-12-31 | $5.11M Ended 2024-12-31 |
| 1 year earlier | $7.30M Ended 2023-12-31 | n/a | $7.5K Ended 2024-12-31 | $5.82M Ended 2023-12-31 |
| 2 years earlier | $6.07M Ended 2022-12-31 | n/a | $686.0K Ended 2023-12-31 | $5.99M Ended 2022-12-31 |
| 3 years earlier | $5.17M Ended 2021-12-31 | n/a | $284.0K Ended 2022-12-31 | $7.81M Ended 2021-12-31 |
| 4 years earlier | $12.63M Ended 2020-12-31 | n/a | n/a | $9.56M Ended 2020-12-31 |